ALLR
What one share of Allarity Therapeutics holds
Pharmaceutical Preparations
We are a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical need. We were founded on the innovation of our novel Drug Response Predictor (DRP®) platform.
Allarity Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.02 |
|---|---|
| Profit | −$0.79 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.88 |
| Cash and investments | $1.07 |
| Book value | $0.22 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2025 | $0.02 | −$0.78 | $0.00 | −$1.03 | — | $0.61 |